<DOC>
	<DOCNO>NCT01035073</DOCNO>
	<brief_summary>The objective study determine time course duloxetine efficacy symptom Major Depressive Disorder ( MDD ) symptoms Soft Tissue Discomfort Syndrome ( STDS ) via use 24-hour Actigraphâ„¢ measure . We hypothesize reduction MDD STDS symptom MDD patient co-morbid STDS symptom . We hypothesize rapid improvement functional outcome rating 24-hour activity MDD patient co-morbid STDS symptom may occur even antidepressant effect observe .</brief_summary>
	<brief_title>Functional Change Efficacy Duloxetine Patients With Co-Morbid Depression &amp; Soft Tissue Discomfort Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>&gt; 17 year old All race ethnicity DSM IVTR Axis I diagnosis MDD Comorbid STDS Baseline 17item Hamilton Depression Rating &gt; 13 Primary Axis I disorder MDD History mania psychosis Actively suicidal Required hospitalization A alcohol substance abuse dependence within precede 3 month Pregnant nursing Unstable medical condition ( STDS ) Narrowangle glaucoma Sensitivity duloxetine , concurrent antidepressant , tranquilizer , mood stabilizer use Hepatic renal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>